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ABSTRACT 
 
Lithium-induced nephrogenic diabetes insipidus (NDI) is associated with severe polyuria, 
aquaporin-2 (AQP2) downregulation and cellular remodelling of the collecting duct (CD). Several 
studies have hypothesized that a likely candidate for lithium entry is the amiloride-sensitive 
epithelial sodium channel (ENaC). To test whether ENaC is involved in lithium absorption, 
transgenic mice deficient of αENaC specifically in the CD (KO mice) and littermate controls were 
subjected to chronic lithium treatment. This resulted in a marked increase in water intake  in 
controls, but not in KO mice. The lithium-treated controls also exhibited polyuria and reduced urine 
osmolality, which was not observed in the KO mice. AQP2 protein levels were decreased in 
cortex/outer medulla and inner medulla (IM) from lithium-treated controls. In KO mice, only AQP2 
levels in IM were partly decreased. Immunohistochemistry showed decreased AQP2 labeling in CD 
of  lithium-treated  controls  compared  to  lithium-treated  KO  mice,  whereas  no  changes     were 
observed in connecting tubule (CNT). Lithium induced an increased H+-ATPase expression in IM 
 
of the controls, but not in the KO mice. No differences in blood lithium concentrations were 
observed between the KO and control mice. Thus, the absence of functional ENaC in CD protects 
the mice from lithium-induced NDI. Apparently, the CNT is able to escape the lithium toxicity. In 
conclusion our data supports the idea that ENaC-mediated lithium-entry into the CD principal cells 
is a crucial step within the pathogenesis of lithium-induced NDI. 
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INTRODUCTION 
 
NDI is characterized by the inability of the kidney to concentrate urine in response to vasopressin. 
The disease is most commonly acquired and often occurs as a side effect in humans subjected to 
different drug treatments, e.g., lithium therapy. Lithium, which is a frequently used drug against 
manic-depressive illness, can cause NDI in up to 20-40% of the patients taking the medication.1 
Chronic lithium treatment of rats results in severe downregulation of AQP2 and AQP3 protein  
levels in parallel with extensive polyuria.2,3 Moreover, lithium causes a remodeling of the rat kidney 
CD, which includes a decreased fraction of principal cells and an increased fraction of intercalated 
cells.4,5 These deleterious effects on the CD are proposed to be linked to lithium accumulation 
within the principal cells. Several studies suggested that a likely candidate for lithium entry is 
ENaC, which is present in the late distal convoluted tubule (DCT) cells, the CNT cells and the CD 
principal cells.6,7 ENaC is a heteromultimeric protein composed of three subunits – α, β and γ.8 
ENaC has a higher permeability for lithium than for sodium.9,10 Moreover, amiloride - a specific 
blocker of ENaC - has been shown to reduce lithium uptake in ENaC-expressing renal cells.11 and  
to block reabsorption in the distal nephron of sodium-depleted rats.12 Recent studies also showed  
that amiloride partially prevents development of lithium-NDI in rats11,13 and partially restores the 
urinary concentrating ability in patients on lithium therapy.14 To possibly provide definitive proof 
whether ENaC is involved in the absorption of lithium, we have taken advantage of transgenic mice 
deficient of αENaC specifically in the CD while leaving ENaC expression in the late DCT and CNT 
intact.15 Under salt restriction, whole-cell voltage clamp of principal cells of the cortical CD (CCD) 
showed no detectable ENaC activity, whereas large amiloride-sensitive currents were observed in 
the CCD of controls15 and in the CNT/DCT of both KO and controls.16 Despite the loss of ENaC 
activity in CD, the animals survived well and were able to maintain sodium and potassium balance, 
even when challenged by one week salt restriction, 23 hours water deprivation, or 2 days potassium 
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loading.15 We have followed these transgenic mice and their littermate controls during chronic 
lithium treatment. 
 
 
RESULTS 
 
Lithium does not induce polyuria and polydipsia in CD-specific αENaC KO mice 
 
Chronic lithium treatment induced increased water intake in the control animals, which was not  
seen in KO mice (Fig 1A). As early as day 4 after starting lithium treatment, water intake increased 
in the lithium-treated controls, whereas it remained at the same level throughout the entire study in 
the lithium-treated KO mice. After 5 days of lithium treatment there was a highly significant 
difference in water intake between the lithium-treated controls and the three other groups, which 
continued the remaining days of the diet. In contrast, water intake of the lithium-treated KO mice 
was not significantly different from the untreated control and KO mice (Fig 1A). The urine output  
of the lithium-treated controls was significantly higher compared to the three other groups (Fig 1B). 
In parallel, the urine osmolality was significantly lower in the lithium-treated controls compared to 
the other groups (Fig 1C). In contrast, there were no significant differences in urine output and urine 
osmolality between the lithium-treated KO mice and the untreated control and KO mice. Thus, 
lithium did not cause polyuria and polydipsia in the lithium-treated KO mice which was seen in the 
lithium-treated controls. 
The urinary sodium and potassium concentration was significantly lower in the lithium-treated 
controls, but not in the lithium-treated KO mice (Table 1). The urinary excretion of sodium and 
potassium was however not changed in any of the two groups after lithium exposure and there were 
no changes in the fractional sodium excretion between the four groups (Table 1). Furthermore, 
serum concentrations of sodium, potassium, urea and creatinine and serum osmolality were 
unaltered in the two groups after lithium exposure (Table 1). The urinary lithium concentration  was 
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significantly lower in the lithium-treated controls compared to the lithium-treated KO mice,  
whereas the urinary lithium excretion was not different between the control and the KO  group 
(Table 1). There were no differences in lithium concentration in the blood between the two lithum- 
treated groups and no changes in lithium clearance and in fractional excretion of lithium were 
observed (Table 1). There was no significant difference in food intake between the two groups 
during the diet and at the end of the diet no significant changes in body weight was observed (Table 
1). 
 
Effect of lithium treatment on AQP2 and H+-ATPase abundance in CD-specific αENaC KO 
mice 
It has previously been shown that lithium treatment of rats causes a dramatic decrease in AQP2 
abundance.2,4 To investigate whether the effect was abolished in the lithium-treated KO mice, 
Western blotting was performed of samples from cortex/OM and IM (Fig 2). Consistent with the 
previous results, chronic lithium treatment resulted in a severe and significant downregulation of 
AQP2 in both IM (Fig 2A) and cortex/OM (Fig 2B). In the cortex/OM of lithium-treated KO  mice, 
AQP2 was significant higher compared with the lithium-treated controls, and no significant 
difference was observed when compared with the untreated KO mice. Thus, lithium treatment did 
not affect total cortical and outer medullary AQP2 expression in the KO mice. In IM, AQP2 
abundance was higher in the lithium-treated KO mice compared to the lithium-treated controls 
although not statistically significant. A significant lower AQP2 expression was seen in the lithium- 
treated KO mice compared to the untreated KO mice. Thus, lithium treatment appears to have some 
effect on AQP2 expression in the IM of KO mice. 
Western blot analysis further showed no significant differences in H+-ATPase abundance in the 
cortex/OM between the lithium-treated controls and the other groups (Fig 2C). In contrast the H+- 
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ATPase expression was significantly increased in the IM of the lithium-treated controls compared  
to the other three groups (Fig 2D). Moreover, no differences between the lithium-treated and 
untreated KO mice were observed. Thus, lithium treatment did not cause changes in the expression 
of H+-ATPase in the IM of KO mice in contrast to the control mice. 
 
Decreased AQP2 labeling in the collecting duct of lithium-treated control mice compared to 
lithium-treated KO mice 
To further investigate AQP2 labeling in the lithium-treated controls and the lithium-treated KO 
mice, we performed immunolabeling on kidney sections from these two groups. In the CD of 
lithium-treated KO mice, a strong AQP2 labeling was seen in IM, ISOM and cortex (Fig 3A-C), 
whereas in the CD of the lithium-treated controls the AQP2 labeling was markedly reduced (Fig 3E-
G). Thus, lithium did not cause a downregulation of AQP2 expression in the CD of the KO mice. In 
the CNT there were no major changes in AQP2 labeling between the two groups (Fig 3D and H) 
indicating that lithium does not affect AQP2 levels in this segment. 
 
Effect of lithium on the density of H+-ATPase positive cells in control and KO mice 
Immunohistochemistry revealed a slight increased density of H+-ATPase positive cells in the 
proximal part of IM and in the ISOM of the lithium-treated controls compared to the lithium-treated 
KO mice (Fig 4A-B and E-F). Moreover, H+-ATPase positive cells localized next to each other 
were seen in the lithium-treated controls. In the CCD of the lithium-treated control mice, H+- 
 
ATPase positive cells were only occasionally localized next to each other and in general no major 
changes in the density of H+-ATPase positive cells was observed in this segment between the two 
groups (Fig 4C and G). In the CNT and DCT the density of H+-ATPase positive cells was not 
different  (Fig 4D and  H). Cellular counting of  H+-ATPase positive cells  in  the CNT     and  DCT 
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revealed no significant changes in the fraction of H+-ATPase positive cells between the two groups 
(36 ± 1.4% in control vs 37 ± 1.0% in KO, n=3 in each group, ns). Moreover, multiple H+-ATPase 
positive cells next to each other were not observed in these segments. Thus, lithium causes a slight 
increased density of intercalated cells in the IM and ISOM of control mice, but not in KO mice. 
Moreover, lithium does not appear to have an effect on the density of intercalated cells in the 
DCT/CNT. 
 
 
DISCUSSION 
 
In this study, we show that the absence of functional ENaC in the CD protects the mice from 
developing lithium-induced NDI. The data provides genetic evidence that ENaC is involved in 
lithium entry into CD principal cells and thus plays a crucial role in the pathogenesis of lithium- 
induced NDI. Interestingly, the lithium-treated KO mice did not show signs of NDI suggesting that 
the CNT is able to escape the lithium toxicity. 
 
 
CD-specific αENaC KO mice are protected from development of NDI 
 
In control mice, lithium treatment caused severe polyuria, low urine osmolality and high water 
intake consistent with an impairment of urinary concentration and thus NDI.2-4,17  In  contrast, 
lithium did not have an effect on the urinary concentrating ability in mice which lack αENaC in the 
CD. Our results are consistent with a recent rat study where co-treatment with lithium and amiloride 
attenuated the lithium-NDI11,13 and with the fact that amiloride administration ameliorates polyuria 
in patients on long-term lithium treatment.18 Furthermore, amiloride prevents lithium-induced  
AQP2 downregulation in mCCDc11 cells.11 We have also previously used lithium protection as a 
positive control for experiments dealing with the role of ENaC in thiazolidinedione-induced fluid- 
retention.19 
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The higher AQP2 expression in the CD of the lithium-treated KO mice compared to the lithium- 
treated controls is consistent with the absence of a urinary concentrating defect in the CD of the KO 
mice. However, western blot analysis showed that lithium did have an effect on AQP2 levels in IM 
of the KO mice as seen by a significant lower AQP2 abundance in the lithium-treated KO mice 
compared to the untreated KO mice. This suggests that the lithium effect on AQP2 levels in the 
IMCD principal cells is not only via an ENaC-mediated entry. Simultaneously administration of 
amiloride and lithium to rats has also been shown not to fully restore AQP2 levels in the IM.11   This 
 
effect may be mediated by PGE2, because lithium increases cyclooxygenase 2 (COX2) expression 
in and PGE2 release from medullary interstitial cells,20 and it is known that PGE2 can inhibit the 
effect of vasopressin on water permeability in the CD.21,22 The decreased AQP2 expression is likely 
not related to a decrease in interstitial osmolality, since furosemide-induced changes in medullary 
tonicity did not affect AQP2 levels in rat IM.23 Finally we cannot exclude that some residual ENaC 
activity remains in the IM of the KO mice,19 but this is unlikely to play a physiologically role. The 
AQP2 downregulation in the IMCD was not correlated with changes in urine output and osmolality 
in the KO mice. Thus the water reabsorption ability did not appear to be impaired. A possibility is 
that lithium did not affect AQP2 trafficking and that a substantial amount of AQP2 remained in the 
apical plasma membrane to sustain water reabsorption. We previously showed that although 
cytoplasmic AQP2 is markedly reduced in rat IM after chronic lithium treatment, some AQP2 still 
remains in the apical membrane.4 
Lithium  administration  was  associated  with  a  slightly  higher  density  of  intercalated  cells (H+- 
 
ATPase positive cells) in the IM and ISOM of the control mice. The increased density of 
intercalated cells was however less pronounced compared to previous studies in rats.4,11,17 The 
phenomenon was not seen in KO mice showing that lithium had no effect on the intercalated cells 
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in these mice. Thus, lithium-induced changes of the intercalated cells require the action of lithium 
on the principal cells. 
Western  blotting  also  revealed  an  upregulation  of  H+-ATPase  protein  levels  in  the  IM  of the 
 
lithium-treated control mice as shown in other studies in rats and is likely due to an increase in the 
density of intercalated cells.11,17 We did not observe changes in H+-ATPase abundance in  
OM/cortex in contrast to previously shown in lithium-treated rats11,17 suggesting that the effect of 
lithium on the intercalated cells in mice is not as dramatic as in rats. 
There was no significant change in plasma lithium concentration between the lithium-treated groups 
and the plasma lithium concentration of 0.6 mM in the lithium-treated control mice corresponds to 
studies in rats using the same protocol.3 
 
ENaC-mediated lithium entry 
 
Under normal conditions, i.e. in sodium-replete conditions, renal lithium clearance is used as a 
measurement of tubular fluid delivery from the proximal tubule. The lithium clearance technique 
assumes that transcellular transport of lithium does not occur in the distal tubule and the CD. 
Previous studies have shown that amiloride-sensitive lithium reabsorption only takes place in the 
distal nephron during conditions with sodium depletion (low sodium diet).12,24  In the present   study 
we showed that lithium-treated mice receiving a normal sodium containing diet develop NDI and 
 
that the absence of ENaC in the CD prevents the development of NDI. Thus, we show that ENaC- 
mediated lithium reabsorption does occur in the CD in mice on a normal salt diet. 
Lithium treatment is known to be associated with natriuresis and experiments with rats using the 
same lithium protocol as in the present study (with the same sodium intake in lithium-treated and 
control rats) have shown that the rate of urinary sodium excretion is increased in lithium-treated 
animals  compared to  controls.3  In  the present  study we did  not  observe  a difference in    urinary 
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sodium excretion between the four mice groups. In another study by Nielsen et al, rats on lithium 
diet consuming the same amount of sodium as the controls also had no differences in urinary 
sodium excretion rates, but these rats had a marked increase in the fractional excretion of sodium.25 
However, no differences in FE-Na+ were observed in this study either. Thus there may be  
differences in the lithium-induced sodium handling in mice and rats. 
 
 
Lithium escape in the CNT 
Mice with ENaC inactivated in the CD did not respond on the lithium treatment suggesting that the 
CNT is able to escape the deleterious effects of lithium. This is in spite of the fact that the CNT  
cells contain ENaC and therefore should be expected to respond to lithium exposure. The CNT 
exhibit the same components for water transport as the CD. AQP2 is expressed in both the CNT and 
the CD although the abundance is lower along the CNT.26,27 Vasopressin-mediated regulation of 
AQP2 expression and trafficking occurs in rat CNT and in mouse and rat the V2-receptor is  equally 
expressed in the CNT and CCD.27,28 Vasopressin also increases adenylate cyclase activity in rat 
CNT.29 
In our study we did not observe differences in AQP2 levels in the CNT of the lithium-treated  
control and KO mice and the density of intercalated cells did not appear to be increased in the two 
groups. Moreover, AQP2 protein levels in OM/cortex were only decreased in the lithium-treated 
control mice and not in the lithium-treated KO mice. Consistently, lithium causes AQP2 
downregulation mainly in the CCD and to a lesser extent in CNT of rats.30 
Differences in ENaC expression between CNT and CCD were observed in rats subjected to  lithium 
 
diet with fixed sodium intake (but not with free access to sodium).25 In these animals, β- and γENaC 
downregulation was observed in CCD and OMCD, but not in CNT. In contrast, increased apical 
labeling of all three ENaC subunits was observed in this segment. This was explained by possible 
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compensatory mechanisms occurring in CNT to limit the renal sodium loss observed in these 
animals.25 
The difference in lithium sensitivity between the CNT and CD could be explained by differences in 
lithium delivery to the CNT and CD resulting in differences in the luminal lithium concentration 
along the CNT and the CD. It is also possible that the lithium intracellular concentration rises to 
toxic levels only in the CD due to a different exit pathway for lithium either through the basolateral 
or the apical plasma membrane in the CNT cells and CD principal cells. Yet another possibility is 
that the expression or the sensitivity to an intracellular target for lithium is different in the CNT and 
the CD. A potentital intracellular target for lithium is glycogen synthase kinase 3β (GSK3β). 
Lithium has been shown to inhibit GSK3 activity in the kidney20 and proteomic studies of IMCD 
isolated from lithium-treated rats revealed an upregulation of the phosphorylated inactive form of 
GSK3β.31 Moreover, an impaired response to vasopressin has recently been shown in CD-specific 
GSK3β KO mice suggesting a potential important role of GSK3β in the vasopressin-mediated water 
reabsorption.32 A recent study showed equal expression of the GSK3β transcript in mouse 
DCT/CNT and CD.33 However, a potential different sensitivity to e.g. phosphorylation and thus 
activity of the GSK3β protein may exist in the two segments. 
 
 
CONCISE METHODS 
 
Experimental protocols 
 
Treatment of transgenic mice: 
 
Lithium chloride was solubilized in water and the solution was added to food to yield a lithium 
concentration of 40 mmol/kg of dry food as previously described.3 CD-specific αENaC KO mice 
(Scnn1alox/lox//HoxB7:Cre, KO mice) and the corresponding control mice (Scnn1alox/lox) (2-4 and 12 
months old) were given lithium containing diet for 24-25 days. In parallel, CD-specific αENaC  KO 
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mice and control mice were given a normal diet for 24 days. All mice were placed in individual 
conventional cages and the water intake was measured daily. From day 22 to day 24 of the 
experiment all mice were placed in metabolic cages to measure urine output and osmolality. During 
the entire experiment mice had free access to food and water. At the end of the experiment blood 
was collected from the eye or from the aorta. The experiment was performed three times and data 
was pooled. 
 
 
Urine and plasma analysis 
 
Osmolarity, sodium and potassium concentration were analyzed at the Laboratoire Central de 
Chimie Clinique, Centre Hospitalier Universitaire Vaudoise (CHUV), Switzerland or at Department 
of Clinical Biochemistry, Skejby University Hospital, Denmark. Lithium concentration was 
measured at Service of Nephrology, CHUV, Switzerland or at Department of Anatomy, Aarhus 
University, Denmark. 
 
 
Western blot analysis 
 
The kidneys were dissected into cortex/outer medulla (OM) and IM and homogenized in dissecting 
buffer as previously described.4 The homogenates were centrifuged for 15 min at 4oC. The total 
protein concentration was measured (Pierce BCA protein assay reagent kit, Pierce, Rockford, IL). 
To confirm equal loading of protein, an initial gel was stained with Coomassie Brilliant blue. SDS- 
PAGE  was  performed  on  12.5%  polyacrylamide  gels  (Pierce,  Rockford,  IL).  After  transfer of 
proteins by electroelution to nitrocellulose membranes, blots were blocked with 5% milk in PBS-T 
(80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20, pH 7.5) for 1 hr and 
incubated with anti-AQP2 antibody (7661 AP, 1:1000) or anti-H+-ATPase (7659 AP, 1:1000).5   The 
 
labeling  was  visualized  with  a  peroxidase-conjugated  secondary  antibody  using  an    enhanced 
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chemiluminescence system (Amersham Pharmacia Biotech, UK). The labeling density was 
quantitated using Quantity One software (Bio Rad laboratories Ltd, Hertfordshire, UK). 
 
 
Immunohistochemistry 
 
Kidneys from lithium-treated KO mice (n=3) and lithium-treated control mice (n=3) were fixed by 
intravascular perfusion with 3% paraformaldehyde in 0.1 M phosphate buffer and subjected to 
paraffin embedding and sectioning (2 µm thick sections). 
Sections were incubated overnight at 4ºC with rabbit polyclonal AQP2 antibody (7661AP, 1:6,000 
dilution) or rabbit polyclonal H+-ATPase antibody (H7659AP, 1:1,000 and 1:2,000 dilution),5 
followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary 
antibody. Labeling was visualized using 3,3’-diaminobenzidine staining.4 
 
Quantification of H+-ATPase positive cells in CNT/DCT 
Cellular counting was performed on kidney sections from lithium-treated KO and lithium-treated 
control mice labeled with H+-ATPase antibody. Counting was performed on electronic images  
taken with an x25 objective. The number of H+-ATPase positive and negative cells with a distinct 
nucleus were counted in the CNT and the DCT of lithium-treated KO mice (1751 cells, n=3) and in 
the CNT/DCT of lithium-treated control mice (1732 cells, n=3). The fraction of H+-ATPase positive 
cells was calculated from the number of H+-ATPase positive cells divided by the total number of 
cells counted for each animal. 
 
 
Statistical analysis 
 
Results are presented as mean ± SE. Data were analyzed by one-way ANOVA and unpaired t test. P 
values <0.05 were considered statistically significant. 
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FIGURE LEGENDS 
 
Figure 1: Water intake (A), urine output (B) and urine osmolality (C) were measured in lithium- 
treated control mice (n= 12, black), lithium-treated KO mice (n=11, white), untreated control mice 
(n=8, bricks) and untreated KO mice (n=7, hexagons). After 4 days of lithium treatment the water 
intake was significantly increased in the lithium-treated control mice compared to the lithium- 
treated KO mice and after 5 days there was a highly significant difference between the lithium- 
treated control mice and the three other groups (A). There were no difference in water intake 
between the lithium-treated KO mice, the untreated control mice and the untreated KO mice during 
the entire diet (A). At the end of the diet the urine output was significantly increased and the urine 
osmolality significantly decreased in the lithium-treated control mice compared to the three other 
groups (B-C), whereas no differences were observed between the lithium-treated KO mice, the 
untreated control mice and the untreated KO mice (B-C). (At day 1, n=6, 6, 3, 3; at day 5-6 and 18- 
19, n=9, 8, 8, 7; at day 8-9, n=11, 11, 8, 7). *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 2: Western blot and corresponding densiometric analysis of AQP2 (A-B) and H+-ATPase 
expression (C-D) in cortex/OM (A and D) and IM (B and D) of untreated control mice (control), 
untreated CD-specific αENaC KO mice (ENaC KO), lithium-treated control mice (Li-control) and 
lithium-treated CD-specific αENaC KO mice (Li-ENaC KO). In cortex/OM, AQP2 protein was 
significantly reduced in Li-control compared to the other three groups, whereas AQP2 levels in the 
Li-ENaC KO was not different from ENaC KO (A). AQP2 protein in IM was significantly lower in 
Li-control compared to the two untreated groups, but not compared to Li-ENaC KO (B). The 
expression of AQP2 in the IM of Li-ENaC KO was significant lower compared to ENaC KO (B). 
No differences in H+-ATPase protein were observed between the Li-control and the other groups  in 
cortex/OM (C). In the IM H+-ATPase was significant higher in the Li-control compared to all  three 
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other groups, whereas the expression in the Li-ENaC KO was not significantly different from the 
untreated groups (D). *p<0.05, **p<0.01, ***p<0.001. 
 
 
Figure 3: Immunohistochemistry using whole kidney sections from lithium-treated CD-specific 
αENaC KO mice (A-D) and lithium-treated control mice (E-H). Sections were incubated with anti- 
AQP2 antibody. In the IM (A and E), ISOM (B and F) and in the CCD (C and G) AQP2 labeling 
was markedly reduced in the lithium-treated control mice (E-G) compared to the lithium-treated 
CD-specific αENaC KO mice (A-C). In the CNT there were no changes in AQP2 labeling between 
the two groups (D and H). 
 
 
Figure 4: Immunohistochemistry using whole kidney sections from lithium-treated CD-specific 
αENaC KO mice (A-D) and lithium-treated control mice (E-H). Sections were incubated with anti- 
H+-ATPase antibody. The density of H+-ATPase-positive cells was slightly increased in the IM and 
ISOM of the lithium-treated control mice (E and F) compared to the lithium-treated CD-specific 
αENaC KO mice (A-B). In the CCD (C and G) and in the CNT (D-H) there were no major changes 
in the density of H+-ATPase-positive cells. 
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Table 1. Urinary and blood measurements from control and KO mice on a normal diet or a Li-diet 
 
 Controls 
Li-diet 
KO mice 
Li-diet 
Controls 
Normal diet 
KO mice 
Normal diet 
 
Body weight (%) 
 
 
Food intake 
(g/g BW) 
 
Serum-Na+, mM 
 
Serum-K+, mM 
 
Serum-osm, 
mosmol/kgH2O 
 
Serum-urea, mM 
 
 
Serum-creatinine, 
uM 
 
Plasma/serum-Li+, 
mM 
 
U-Na+, mmol/24 h 
U-Na+, mM 
FE-Na+, % 
 
99.0 ± 2.2+ 
(n=12) 
 
0.25 ± 0.03 
(n=12) 
 
149.7 ± 0.8 
(n=6) 
 
4.3 ± 0.2 
(n=6) 
 
345 ± 3 
(n=6) 
 
7.7 ± 0.4 
(n=6) 
 
27 ± 1.4 
(n=9) 
 
0.61 ± 0.16 
(n=7) 
 
0.16 ± 0.03 
(n=11) 
 
23 ± 4## 
(n=11) 
 
0.47 ± 0.06 
(n=5) 
 
104.2 ± 1.7 
(n=11) 
 
0.22 ± 0.02 
(n=11) 
 
151.4 ± 1.0 
(n=5) 
 
4.4 
(n=2) 
 
334 ± 8 
(n=3) 
 
7.6 
(n=2) 
 
27 ± 2.2 
(n=8) 
 
0.38 ± 0.07 
(n=8) 
 
0.15 ± 0.03 
(n=11) 
 
97 ± 13 
(n=11) 
 
0.97 ± 0.19 
(n=5) 
 
107.4 ± 2.3 
(n=8) 
 
0.26 ± 0.03 
(n=8) 
 
147.3 ± 0.7 
(n=3) 
 
4.2 ± 0.4 
(n=3) 
 
341 
(n=2) 
 
8.2 ± 0.6 
(n=3) 
 
28 ± 1.0 
(n=6) 
 
0.75 ± 0.04 x 10-3 
(n=3) 
 
0.13 ± 0.02 
(n=7) 
 
91 ± 13 
(n=7) 
 
0.77 ± 0.18 
(n=3) 
 
105.8 ± 1.1 
(n=7) 
 
0.24 ± 0.03 
(n=7) 
 
147.0 ± 1.0 
(n=3) 
 
4.5 
(n=1) 
 
344 ± 4 
(n=3) 
 
7.4 
(n=1) 
 
27 ± 1.1 
(n=6) 
 
0.84 ± 0.06 x 10-3 
(n=3) 
 
0.14 ± 0.01 
(n=7) 
 
108 ± 20 
(n=7) 
 
1.04 ± 0.22 
(n=3) 
U-K+, mmol/24 h 
 
U-K+, mM 
0.54 ± 0.07 
(n=11) 
 
79 ± 16## 
(n=11) 
0.48 ± 0.07 
(n=11) 
 
328 ± 50 
(n=11) 
0.40 ± 0.03 
(n=7) 
 
324 ± 70 
(n=7) 
0.46 ± 0.03 
(n=7) 
 
349 ± 62 
(n=7) 
C-creatinine, 
µl*min-1*g-1 
 
U-creatinine, µM 
 
U-Li+, mmol/24 h 
9.7 ± 2.4 
(n=9) 
 
1819 ± 541 
(n=12) 
 
0.08 ± 0.01 
(n=11) 
8.3 ± 3.7 
(n=8) 
 
4260 ± 732 
(n=11) 
 
0.05 ± 0.01 
(n=12) 
6.0 ± 1.5 
(n=6) 
 
3577 ± 500 
(n=7) 
 
0.20 ± 0.02 x 10-3 
(n=3) 
7.7 ± 2.3 
(n=6) 
 
4207 ± 935 
(n=7) 
 
0.17 ± 0.005 x 10-3 
(n=3) 
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U-Li+, mM 
 
C- Li+, 
µl*min-1*g-1 
FE- Li+, % 
13.4 ± 2.5** 
(n=11) 
 
5.2 ± 0.9 
(n=7) 
 
70 ± 23 
(n=7) 
35.5 ± 6.1 
(n=12) 
 
4.8 ± 1.0 
(n=3) 
 
197 ± 105 
(n=8) 
93 ± 25 x 10-3 
(n=3) 
 
6.2 ± 0.8 
(n=3) 
 
69 ± 1 
(n=3) 
105 ± 15 x 10-3 
(n=3) 
 
6.3 ± 0.8 
(n=3) 
 
51 ± 10 
(n=3) 
 
 
 
All measurements are from day 24 except the body weight, which is measured at day 21. +, p<0.05 (controls 
on Li-diet vs controls on normal diet). ##, p<0.01 (controls on a Li-diet vs three other groups). **, p<0.01 
(controls on a Li-diet vs KO on a Li-diet). The body weight in percentage is calculated as a fraction of day 0 
(beginning of the experiment). 
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